BRPI1006759A2 - método para produção de uma composição de leucócitos ativados, composição de leucócitos ativados para uso na cicatrização e método para tratamento de feridas - Google Patents

método para produção de uma composição de leucócitos ativados, composição de leucócitos ativados para uso na cicatrização e método para tratamento de feridas

Info

Publication number
BRPI1006759A2
BRPI1006759A2 BRPI1006759A BRPI1006759A BRPI1006759A2 BR PI1006759 A2 BRPI1006759 A2 BR PI1006759A2 BR PI1006759 A BRPI1006759 A BR PI1006759A BR PI1006759 A BRPI1006759 A BR PI1006759A BR PI1006759 A2 BRPI1006759 A2 BR PI1006759A2
Authority
BR
Brazil
Prior art keywords
activated leukocyte
leukocyte composition
healing
producing
wound treatment
Prior art date
Application number
BRPI1006759A
Other languages
English (en)
Portuguese (pt)
Inventor
Adi Zuloff-Shani
Eilat Bain
Eilat Shinar
Irene Ginis
Marina Bubis
Mitchell Shirvan
Orit Frenkel
Original Assignee
Macrocure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrocure Ltd filed Critical Macrocure Ltd
Publication of BRPI1006759A2 publication Critical patent/BRPI1006759A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Surgery (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
BRPI1006759A 2009-03-05 2010-03-05 método para produção de uma composição de leucócitos ativados, composição de leucócitos ativados para uso na cicatrização e método para tratamento de feridas BRPI1006759A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20929809P 2009-03-05 2009-03-05
US21158709P 2009-04-01 2009-04-01
PCT/IB2010/000882 WO2010100570A2 (en) 2009-03-05 2010-03-05 Activated leukocyte composition

Publications (1)

Publication Number Publication Date
BRPI1006759A2 true BRPI1006759A2 (pt) 2016-03-15

Family

ID=42710060

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006759A BRPI1006759A2 (pt) 2009-03-05 2010-03-05 método para produção de uma composição de leucócitos ativados, composição de leucócitos ativados para uso na cicatrização e método para tratamento de feridas

Country Status (15)

Country Link
EP (2) EP2650001B1 (enExample)
JP (2) JP5713924B2 (enExample)
KR (1) KR101548783B1 (enExample)
CN (1) CN102438635B (enExample)
AU (1) AU2010220132B2 (enExample)
BR (1) BRPI1006759A2 (enExample)
CA (2) CA2867976A1 (enExample)
DK (1) DK2403509T3 (enExample)
ES (1) ES2428102T3 (enExample)
IL (1) IL214953A0 (enExample)
MX (1) MX2011009277A (enExample)
PL (1) PL2403509T3 (enExample)
RU (2) RU2015102067A (enExample)
WO (1) WO2010100570A2 (enExample)
ZA (1) ZA201107269B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574902B2 (en) 2009-03-05 2013-11-05 Macrocure Ltd. Activated leukocyte composition and uses for wound healing
BR112013005610A2 (pt) * 2010-09-09 2019-09-24 Macrocure Ltd sobrenadante condicionado de leucócito, alcs, método para o tratamento de uma ferida, método para a inibição do surgimento de infecção em uma ferida, método, sobrenadante e produto
WO2013136182A1 (en) 2012-03-15 2013-09-19 Macrocure, Ltd. Activated immunostimulatory cell composition and uses thereof
RU2014140795A (ru) 2012-03-15 2016-05-10 Макрокьюэ, Лтд. Активированная иммуностимулирующая клеточная композиция, используемая для лечения инфекционных заболеваний
EP2781224A1 (en) * 2013-03-18 2014-09-24 Khorionyx Implantable preparations comrpsing globin insoluble at physiological pH and serum for regeneration of tissues and treatment of wounds.
CN107427535A (zh) 2015-02-16 2017-12-01 纳雅康医疗有限公司 经修饰的血凝块
GB201618106D0 (en) 2016-10-26 2016-12-07 Lift Biosciences Ltd Cancer-killing cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60120821A (ja) * 1983-12-05 1985-06-28 Asahi Chem Ind Co Ltd 悪性腫瘍治療用白血球刺激材および刺激方法
US4751001A (en) * 1984-09-24 1988-06-14 Becton Dickinson And Company Blood partitioning apparatus
JPH02167071A (ja) * 1988-12-19 1990-06-27 Terumo Corp 非ヒト動物由来白血球系細胞の分離材、分離器および分離方法
JPH07102151B2 (ja) * 1994-06-03 1995-11-08 中外製薬株式会社 新規なポリペプチドの製造法
IL110195A (en) * 1994-07-03 2003-10-31 David Danon Method and system for cultivating macrophages
US6146890A (en) 1994-07-03 2000-11-14 Danon; David Method and system for cultivating macrophages
JP3201610B2 (ja) * 1995-03-17 2001-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍を処置する方法
JPH10259134A (ja) * 1997-01-16 1998-09-29 Sekisui Chem Co Ltd 創傷治癒促進剤
RU2143685C1 (ru) * 1998-05-19 1999-12-27 Коган Александр Харитонович Способ дифференциального подсчета гранулоцитов, моноцитов и лимфоцитов
EP1731175B1 (en) * 1998-11-12 2009-09-30 International Manufacturing Group, Inc. Hemostatic cross-linked dextran beads useful for rapid blood coagulation and hemostatis
AU2002353465B2 (en) * 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
JP4108393B2 (ja) * 2002-07-15 2008-06-25 テルモ株式会社 細胞増殖剤の製造方法
JP4245324B2 (ja) * 2002-10-09 2009-03-25 旭化成クラレメディカル株式会社 単球の分離回収方法
EP2198873A1 (en) * 2008-12-18 2010-06-23 Aposcience AG Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
EP2201954A1 (en) * 2008-12-18 2010-06-30 Aposcience AG Pharmaceutical preparation

Also Published As

Publication number Publication date
RU2011139016A (ru) 2013-04-10
KR101548783B1 (ko) 2015-08-31
WO2010100570A3 (en) 2010-12-16
RU2548741C2 (ru) 2015-04-20
CA2754190A1 (en) 2010-09-10
JP2015129180A (ja) 2015-07-16
RU2015102067A (ru) 2015-06-20
EP2403509B1 (en) 2013-08-21
ZA201107269B (en) 2014-03-26
CA2867976A1 (en) 2010-09-10
EP2403509A2 (en) 2012-01-11
DK2403509T3 (da) 2013-09-16
WO2010100570A2 (en) 2010-09-10
KR20120002530A (ko) 2012-01-05
EP2650001A1 (en) 2013-10-16
CN102438635A (zh) 2012-05-02
CN102438635B (zh) 2014-09-17
AU2010220132A1 (en) 2011-10-13
JP5713924B2 (ja) 2015-05-07
AU2010220132B2 (en) 2013-10-10
IL214953A0 (en) 2011-11-30
EP2650001B1 (en) 2016-09-07
ES2428102T3 (es) 2013-11-05
MX2011009277A (es) 2011-12-16
PL2403509T3 (pl) 2013-11-29
JP2012519681A (ja) 2012-08-30

Similar Documents

Publication Publication Date Title
PL3318255T3 (pl) Kompozycje i sposoby leczenia udaru u pacjenta z jednoczesną terapią statyną
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
SI3184114T1 (sl) Postopek, cev in naprava za pripravo sestavka za zdravljenje ran
BRPI1011482A2 (pt) composição para uso na redução da transmissão de patógenos humanos
BRPI1016147A2 (pt) sistema intrauterino para uso no tratamento de uma condição médica, e, método para a fabricação de um sistema intrauterino
BRPI1015979A2 (pt) esponja porosa hemostática, e, métodos para fabricar uma esponja porosa hemostática, e para tratar um ferimento.
IL216263A0 (en) Devices, methods and kits for forming tracts in tissue
BRPI0820212A2 (pt) Dispositivo para tratamento de fraturas, método para tratamento de fraturas, e, kit para tratamento de fraturas
BR112013018037A2 (pt) método para a produção de enxerto na derme de um animal, em particular derme porcina, enxerto e uso do enxerto
BRPI0810806A2 (pt) Método para tratar uma lesão cutânea em um indivíduo
IL210754A0 (en) Devices, methods, and kits for forming tracts in tissue
DK2771041T3 (da) Sammensætninger og anvendelse deraf ved knogleheling
BRPI0817198A2 (pt) (ciclopropilfenil)feniloxalamidas, método para a produção das mesmas, e uso das mesmas como um medicamento
BRPI1007779A2 (pt) perexilina, método para tratamento de hcm, programa de tratamento para tratar hcm e uso da perexilina
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BRPI0910760A2 (pt) método para remineralizar tecido, agente remineralizador, e, kit
IL218780A0 (en) Devices,, methods, and kits for forming tracts in tissue
BR112013014522A2 (pt) anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
BRPI1010617A2 (pt) uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição.
BR112012027145A2 (pt) emulsão, composição de uso final e método para tratar uma condição cutânea
GB201305198D0 (en) Kits, components and methods for tissue reconstruction
BR112012001344A2 (pt) derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças
PL2851096T3 (pl) Kompozycja do naprawy tkanki chrzęstnej, sposób jej wytwarzania oraz jej zastosowanie
BR112012014664A2 (pt) fio elástico de poliuretano e método para produzir fio elástico de poliuretano

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]